About Genmab
Genmab is a company based in Copenhagen (Denmark) founded in 1999 by Jan van de Winkel. The company has 2,680 employees as of December 31, 2024. Genmab has completed 2 acquisitions, including Merus and Profound Bio. Genmab operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Copenhagen, Denmark
- Employees 2680 as on 31 Dec, 2024
- Founders Jan van de Winkel
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genmab A/S
-
Annual Revenue
$3 B (USD)30.67as on Dec 31, 2024
-
Net Profit
$1.09 B (USD)80.24as on Dec 31, 2024
-
EBITDA
$1.03 B (USD)31.3as on Dec 31, 2024
-
Latest Funding Round
$181.27 M (USD), Post-IPO
Jan 23, 2014
- Investors
-
Employee Count
2680
as on Dec 31, 2024
-
Investments & Acquisitions
Merus
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genmab
Genmab is a publicly listed company on the OMXCOP with ticker symbol GMAB in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Genmab
Unlock access to complete
Unlock access to complete
Leadership Team
79 people
Software Development Team
53 people
Human Resources and Administration
27 people
Finance and Accounting
25 people
Product Management Team
20 people
Operations Team
15 people
Senior Team
14 people
Legal and Compliance
13 people
Unlock access to complete
Funding Insights of Genmab
Investors in Genmab
Genmab has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Locked | Locked | Locked |
Investor details for Genmab
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genmab
Genmab has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Merus and Profound Bio.
Investment portfolio details for Genmab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel cancer therapies are developed via antibody-drug conjugates.
|
Locked | Locked | 2018 | Locked | |
|
Antibody-based drugs for cancer treatment are developed using bispecific engineering.
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Genmab
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Genmab
Detailed financials for Genmab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genmab Comparisons
Peer comparison for Genmab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genmab
Genmab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Genmab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genmab
Complete news archive for Genmab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genmab
Genmab was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Genmab is headquartered in Copenhagen, Denmark.
Jan van de Winkel is the current CEO of Genmab. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Genmab is 2,680.
Annual revenue of Genmab is $3B as on Dec 31, 2024.
Genmab was established in 1999 in Copenhagen, Denmark, within the biotechnology sector. Antibody-based treatments for cancer and autoimmune conditions are created using proprietary platforms such as DuoBody, HexaBody, DuoHexaBody, and HexElect. A product pipeline is maintained, featuring items like Teprotumumab for thyroid eye disease, Tisotumab vedotin for certain solid tumors and cervical cancer, and Darzalex for multiple myeloma, with operations centered on research and development.
Genmab's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Yes, Genmab is publicly traded on OMXCOP under the ticker symbol GMAB.
Genmab has made 2 acquisitions, including Merus, and Profound Bio.
Genmab has 1 investor. Key investors include GSK.
The ticker symbol of Genmab is GMAB on OMXCOP.